E

    Edesa Biotech Inc (EDSA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.74
    +0.12 (+2.49%)

    Market Cap: $45.65M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    58%(22/38)
    Avg Surprise
    -107.26%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.84
    Range$-0.84 - $-0.83
    3 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$N/A
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-N/A---
    Sep 26EST
    		-$-0.84---
    Jun 26
    Reported Aug 7
    		$-0.60$-0.44-36.36%Miss-140.0%
    Mar 26
    Reported May 14
    		$-0.49$-0.26-88.46%Miss-63.3%
    Dec 25
    Reported Feb 13
    		$-0.28$-0.45+37.78%Beat+41.7%
    Sep 25
    Reported Dec 12
    		$-0.32$-0.56+42.86%Beat-10.3%
    Jun 25
    Reported Aug 8
    		$-0.25$-0.26+3.85%Beat+51.9%
    Mar 25
    Reported May 14
    		$-0.30$-0.29-3.45%Miss+48.3%
    Dec 24
    Reported Feb 14
    		$-0.48$-0.31-54.84%Miss+11.1%
    Sep 24
    Reported Dec 13
    		$-0.29$-0.54+46.30%Beat+51.7%
    Jun 24
    Reported Aug 9
    		$-0.52$-0.58+10.34%Beat+25.7%
    Mar 24
    Reported May 10
    		$-0.58$-0.69+15.94%Beat+31.0%
    Dec 23
    Reported Feb 9
    		$-0.54N/A+55.37%Beat+40.7%
    Sep 23
    Reported Dec 15
    		$-0.60$-0.71+15.49%Beat-2900.0%
    Jun 23
    Reported Aug 9
    		$-0.70$-1.21+42.15%Beat+73.0%
    Mar 23
    Reported May 11
    		$-0.84$-1.21+30.58%Beat+63.6%
    Dec 22
    Reported Feb 10
    		$-0.91$-1.33+31.58%Beat-175.8%
    Sep 22
    Reported Dec 16
    		$-0.02N/A+94.87%Beat+99.3%
    Jun 22
    Reported Aug 12
    		$-2.59$-3.01+13.95%Beat+19.1%
    Mar 22
    Reported May 13
    		$-2.31$-2.57+10.12%Beat+59.3%
    Dec 21
    Reported Feb 14
    		$-0.33$-0.40+17.50%Beat+81.9%
    Sep 21
    Reported Dec 28
    		$-2.86$-2.94+2.72%Beat-1200.0%
    Jun 21
    Reported Aug 13
    		$-3.20$-0.98-226.53%Miss-128.6%
    Mar 21
    Reported May 14
    		$-5.67$-2.73-107.69%Miss-376.5%
    Dec 20
    Reported Feb 16
    		$-1.82$-1.54-18.18%Miss-1113.3%
    Sep 20
    Reported Dec 7
    		$-0.22$-0.20-10.00%Miss+60.0%
    Jun 20
    Reported Aug 12
    		$-1.40$-1.61+13.04%Beat-366.7%
    Mar 20
    Reported May 15
    		$-1.19$-1.82+34.62%Beat+36.0%
    Dec 19
    Reported Feb 13
    		$-0.15N/AN/ABeat+90.4%
    Sep 19
    Reported Dec 12
    		$-0.55N/A+68.39%Beat-129.2%
    Jun 19
    Reported Aug 14
    		$-0.30N/A+81.48%Beat+88.9%
    Mar 19
    Reported May 8
    		$-1.86$-1.56-19.23%Miss-106.7%
    Dec 18
    Reported Feb 5
    		$-1.56$-0.23-578.26%Miss-67.7%
    Sep 18
    Reported Nov 30
    		$-0.24$-0.24+0.00%Beat+70.4%
    Jun 18
    Reported Aug 8
    		$-2.70$-0.10-2600.00%Miss-221.4%
    Mar 18
    Reported May 8
    		$-0.90$-0.09-900.00%Miss-16.9%
    Dec 17
    Reported Feb 5
    		$-0.93$-0.70-32.86%Miss+11.4%
    Sep 17
    Reported Dec 1
    		$-0.81$0.00N/ABeat+11.0%
    Jun 17
    Reported Aug 9
    		$-0.84$-0.77-9.09%Miss-
    Mar 17
    Reported May 9
    		$-0.77$-0.70-10.00%Miss-
    Dec 16
    Reported Feb 6
    		$-1.05$-0.70-50.00%Miss-
    Sep 16
    Reported Dec 14
    		$-0.91$-0.91+0.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-2.80EV/EBITDA-1.25x
    Price/FCF-4.76xFCF Yield-20.99%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-122.90%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio2.76xQuick Ratio2.76x
    Trading Statistics
    Beta1.08Avg Volume89.77K
    52-Week High$20.3252-Week Low$0.72

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.84
    SMA 20$5.09
    SMA 50$6.00
    SMA 200$5.22
    EMA 10$4.82
    EMA 20$5.07
    EMA 50$5.84
    EMA 200$5.58

    MACD

    Line: -0.36Signal: -0.37Hist: 0.01

    ADX

    ADX: 15.3+DI: 15.8-DI: 17.9

    Aroon & PSAR

    Aroon Up60.0
    Aroon Down80.0
    PSAR$5.89

    Bollinger Bands

    Upper Band$5.97
    Lower Band$4.20
    %B Position3480%(Upper)
    Band Width0.30

    RSI (14-Day)

    Neutral
    41.4

    Momentum Oscillators

    Stoch %K20.8
    Stoch %D21.9
    Williams %R-75.9
    ROC (10d)-16.2%
    Momentum-0.92
    CCI (20d)-78.9
    MFI (14d)39.1

    Volatility Measures

    ATR (14d)$0.62(13.0%)
    StdDev (20d)0.44
    Hist Vol92.7%(High)

    Volume Flow

    VWAP$4.70
    OBV206.7M
    AD Line96.2M
    CMF (20d)-0.317

    Volume Metrics

    Avg Vol (20d)92.3K
    Vol Ratio0.9x
    VWMA (20d)$4.95

    Pivot Points

    R3$5.29
    R2$5.11
    R1$4.86
    Pivot Point$4.68
    S1$4.44
    S2$4.26
    S3$4.02

    Advanced Oscillators

    TSI-21.25
    Ultimate Osc39.3
    KST-169.21

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$50,918$0$0$0$0$0$0$0$0$0$-1,118,100
    Cost of Revenue$25,644$25,872$25,459$25,868$25,787$24,509$43,109$44,206$51,415$45,397$45,031$45,969
    Gross Profit$-25,644$-25,872$-25,459$-25,868$-25,787$-24,509$-43,109$-44,206$-51,415$-45,397$-45,031$-1,164,069
    Operating Expenses$5.52M$4.27M$2.32M$2.44M$1.90M$1.64M$1.90M$1.00M$1.93M$2.18M$1.81M$1.79M
    R&D$3.96M$2.77M$1.12M$1.23M$939,067$484,306$1.02M$103,867$897,305$1.18M$704,458$953,399
    SG&A$1.56M$1.53M$1.22M$1.24M$964,676$1.15M$878,871$900,529$1.04M$1.04M$1.15M$1.42M
    Operating Income$-5,519,549$-4,296,994$-2,341,383$-2,470,248$-1,903,743$-1,638,886$-1,898,689$-1,004,396$-1,932,445$-2,220,470$-1,857,430$-2,369,663
    Interest Income$0$639$47$55$572$265$1,666$16,491$32,848$43,193$60,966$71,945
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$120,520
    Income Before Tax$-5,407,611$-4,217,532$-2,247,669$-2,228,358$-1,749,464$-1,589,648$-1,617,253$-962,051$-1,668,212$-1,860,531$-1,678,451$-1,720,343
    Income Tax Expense$0$800$0$0$0$800$0$0$4$800$-1$122,791
    Net Income$-5,407,611$-4,218,332$-2,247,669$-2,228,358$-1,749,464$-1,590,448$-1,617,253$-962,051$-1,668,212$-1,861,331$-1,678,451$-1,720,343
    EBITDA$-5,519,549$-4,271,122$-2,315,924$-2,197,230$-1,694,675$-1,562,109$-1,554,385$-917,844$-1,616,796$-1,871,075$-1,691,564$-1,666,707
    EBIT$-5,545,193$-4,296,994$-2,341,383$-2,223,098$-1,720,462$-1,586,618$-1,597,494$-962,050$-1,668,211$-1,916,472$-1,736,595$-1,712,676
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about EDSA

    News

    Edesa Biotech (NASDAQ: EDSA) major holder's multi-million-share stake detailed

    Dr. Pardeep Nijhawan and associated entities have filed an amended Schedule 13D, disclosing beneficial ownership of 2,613,492 common shares of Edesa Biotech, Inc. (EDSA), which represents approximately 16.31% of the company's outstanding shares. This includes direct holdings, options, RSUs, warrants, and preferred shares, based on 14,193,356 common shares outstanding as of August 25, 2026. The filing also notes recent grants of restricted share units to Dr. Nijhawan in lieu of partial salary.

    Stock Titan•8/25/26•
    Neutral

    Velan Capital lifts Edesa Biotech (EDSA) stake to 9.99% with warrant leverage

    Velan Capital-affiliated entities have increased their beneficial ownership in Edesa Biotech (EDSA) to 9.99% following an underwritten public offering on August 21, 2026. This increase includes the acquisition of additional common shares and warrants by Velan Master, Horizon, and Opportunity II funds. Without certain ownership limitations on warrants, the group would collectively own approximately 27.8% of outstanding shares.

    Stock Titan•8/25/26•
    Somewhat-Bullish

    EDSA: Recruitment in Phase 2 Vitiligo Study Set to Get Underway

    Edesa Biotech is preparing to initiate a Phase 2 study for EB06, its anti-CXCL10 monoclonal antibody, targeting moderate-to-severe non-segmental vitiligo, with recruitment expected to begin shortly. The company recently reported positive exploratory data for paridiprubart (EB05) in acute kidney injury (AKI) patients, showing a significant reduction in 28-day mortality and major adverse kidney events. Edesa also announced financial results for Q3 fiscal year 2026, and a public offering aiming to raise approximately $25 million to support its clinical development programs.

    Zacks Investment Research•8/24/26•
    Bullish

    Edesa Biotech Stock Sinks After Fresh Capital Raise

    Edesa Biotech (NASDAQ: EDSA) shares fell nearly 13% after the company announced a $25 million public stock offering. The offering involves 3.87 million common shares and pre-funded warrants, raising dilution concerns for existing shareholders. The proceeds will fund general corporate purposes, including R&D, manufacturing, and capital expenditures.

    TradingView•8/21/26•
    Bearish

    Edesa Biotech Enters Underwriting Deal With Guggenheim for $23.1M Equity Offering

    Edesa Biotech (EDSA) has entered into an underwriting agreement with Guggenheim Securities for a public offering of common shares and warrants, expected to generate approximately $23.1 million in net proceeds. The offering includes 3,870,500 common shares and 675,000 pre-funded warrants, with an option for additional shares. The funds will be used for general corporate purposes, including working capital, capital expenditures, and R&D and manufacturing expenses.

    TradingView•8/20/26•
    Somewhat-Bullish

    Frequently Asked Questions About EDSA

    Does EDSA pay dividends?
    Edesa Biotech Inc (EDSA) does not currently pay a regular dividend.
    What is EDSA's market cap?
    Edesa Biotech Inc (EDSA) has a market capitalization of $45.65M with a current stock price of $4.74.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In